PUBBLICATO IL NUOVO NUMERO DELLA WHO PHARMACEUTICAL NEWSLETTER

Fonte: WHO. N 1, febbraio 2018

E' disponibile il nuovo numero della WHO Pharmaceutical newsletter.

In questo numero:

REGULATORY MATTERS
• Aripiprazole.
• Cladribine
• Clozapine
• Dengvaxia®
• Edoxaban
• Eluxadoline
• Epoetins
• Fingolimod
• Flucloxacillin and concomitant paracetamol
• Gadolinium-based contrast agents (GBCAs)
• Idelalisib
• Iodine-containing contrast agents
• Ipilimumab
• Lenvatinib
• Long-acting beta agonists (LABAs) and inhaled corticosteroids (ICS)
• Opioid cough and cold medicines (prescription)
• Paracetamol (modified-release) containing products.
• Proton Pump Inhibitors (PPIs)
• Sedative and anaesthetic drugs (other than benzodiazepines and barbiturates)
• Tacrolimus products (oral)
• Teriparatide

SAFETY OF MEDICINE
• Antiepileptic drugs
• Benzodiazepines and barbiturates
• Chlorhexidine
• Ibuprofen
• Interferon beta-1a
• Quinine
• Radium-223 dichloride in combination with abiraterone and prednisone/prednisolone
• Rolapitant
• SGLT2 inhibitor

SIGNAL
• Ciprofloxacin, enalapril and acute kidney injury: strengthening of a drug interaction signal
• Ivermectin and serious neurological events

FEATURE
• Recommendations from the 40th Annual Meeting of Representatives of the National Pharmacovigilance Centres Participating in the WHO Programme for International Drug Monitoring